Ablation versus medication as initial therapy for paroxysmal atrial fibrillation: An updated meta‐analysis of randomized controlled trials

Abstract

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Catheter ablation for atrial fibrillation in the elderly >75 years old: Systematic review and meta‐analysis

“…Catheter ablation is an effective treatment for symptomatic AF and decreases the risk of AF recurrences compared to antiarrhythmic drug therapy. 4,5 Outcome data derived from recent randomized controlled trials (RCT) support catheter ablation as a first-line therapy in certain patients with paroxysmal AF. 6,7 Despite a lower risk of AF recurrence with ablation, in the CABANA trial for the primary endpoint of death, disabling stroke, serious bleeding, and cardiac arrest, sub-analysis by age revealed significantly better outcomes with ablation in younger patients (<65 years, OR: 0.52: 0.27-1.0) that trended towards harm with ablation in older patients (>75 years, OR:…”

“…Catheter ablation is an effective treatment for symptomatic AF and decreases the risk of AF recurrences compared to antiarrhythmic drug therapy 4,5 . Outcome data derived from recent randomized controlled trials (RCT) support catheter ablation as a first‐line therapy in certain patients with paroxysmal AF 6,7 .…”

Atrial fibrillation ablation in hemodialysis patients: a new realm on the overlooked

“…Nonetheless, the tradeoffs between benefits and risks on these options are formidable, for example; ones might not have significant palpitation but suffer from the side effects of medications or the need to proceed with an open heart surgery for MAZE procedure. Catheter ablation (CA) has been later emerging, widely adopted and accepted among the greatest armaments in controlling the AF burdens, improving QoL, reducing HF admission and mortalities in certain populations (3)(4)(5).…”